1. Home
  2. HCI vs NKTR Comparison

HCI vs NKTR Comparison

Compare HCI & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCI Group Inc.

HCI

HCI Group Inc.

HOLD

Current Price

$182.65

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$72.67

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCI
NKTR
Founded
2006
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
HCI
NKTR
Price
$182.65
$72.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$230.00
$146.67
AVG Volume (30 Days)
142.7K
637.4K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
1.03%
N/A
EPS Growth
155.57
N/A
EPS
11.05
N/A
Revenue
$900,946,000.00
$307,711,000.00
Revenue This Year
$11.44
N/A
Revenue Next Year
$7.67
N/A
P/E Ratio
$16.68
N/A
Revenue Growth
20.12
86.00
52 Week Low
$144.75
$25.35
52 Week High
$210.50
$109.00

Technical Indicators

Market Signals
Indicator
HCI
NKTR
Relative Strength Index (RSI) 55.36 56.02
Support Level $183.13 $64.28
Resistance Level $197.92 $75.82
Average True Range (ATR) 5.18 2.66
MACD 0.01 0.02
Stochastic Oscillator 37.09 68.35

Price Performance

Historical Comparison
HCI
NKTR

About HCI HCI Group Inc.

HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: